(Reuters) -AstraZeneca said on Thursday its experimental therapy gefurulimab met the main goal of a late-stage study looking into improving symptoms of a chronic, autoimmune condition known as generalised myasthenia gravis in adults.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Sonia Cheema)
Comments